Skip to main content

LDN Use in Cognitive Decline, Lyme Disease, and Hashimoto’s Thyroiditis

Speaker

Pamela Smith, MD

Abstract

This interactive seminar will examine the biochemistry and physiology of low dose naltrexone. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, low dose naltrexone (LDN) can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases as well as chronic Lyme disease and cognitive decline.

Objectives

  • Learn new therapies for cognitive decline
  • Recognize that inflammation is present in all forms of memory loss
  • Examine the use of LDN for cognitive decline
  • Recognize that chronic Lyme disease can lead to cognitive decline
  • Explore the use of LDN for Lyme disease
  • Understand that LDN is an effective therapy for Hashimoto’s thyroiditis
  • Understand that hypothyroidism is a cause of declining cognition and that Hashimoto’s thyroiditis is present in 70% of patients with hypothyroidism
  • Learn that LDN is an effective therapy for Hashimoto’s thyroiditis

This seminar begins with examining the role of inflammation and cognitive decline. It will then analyze the anti-inflammatory effects of low-dose naltrexone and its positive effects upon memory by investigating its role in the treatment of two known causes of memory loss: Lyme disease and Hashimoto’s thyroiditis.